Clemens Christian Cyran1, Philipp Marius Paprottka1, Bettina Schwarz2, Jobst von Einem1, Steven Sourbron1, Olaf Dietrich1, Rabea Hinkel3, Christiane J. Bruns2, Hubertus Pietsch4, Bernd J. Wintersperger1, Maximilian F. Reiser1, Konstantin Nikolaou1
1Institute of Clinical Radiology, Munich University Hospitals - Campus Grosshadern, Munich, Germany; 2Department of Surgery, Munich University Hospitals - Campus Grosshadern, Munich, Germany; 3Department of Cardiology, Munich University Hospitals - Campus Grosshadern, Munich, Germany; 4Contrast Media Research, Bayer Schering Pharma AG, Berlin, Germany
The purpose of this study was to investigate the effects of Sorafenib on experimental prostate carcinomas in rats by dynamic MRI enhanced with Gadobutrol. Target parameters were tumor perfusion and tumor endothelial permeability. Tumor perfusion (ml/100ml/min), assayed by DCE-MRI enhanced with the small molecular contrast medium Gadobutrol, decreased significantly (p<0.01) in experimental prostate carcinomas treated with a daily, one-week treatment course of Sorafenib (10mg/kg bodyweight). In the control group, tumor perfusion increased significantly (p<0.05) over the experimental course of 7 days. No significant change was observed regarding the endothelial permeability in tumors, neither in the therapy nor in control group.